Johnson and Johnson: Nipocalimab Demonstrates Sustained Disease Control in Adolescents Living With Generalized Myasthenia Gravis in Phase 2/3 Study
October 16, 2024
October 16, 2024
NEW BRUNSWICK, New Jersey, Oct. 16 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 - 17 years, broadening the population in which nipocalimab has been studied
* * *
SAVANNAH, Ga. (October 15, 2024) - Johnson & Johnson today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab i . . .
* * *
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 - 17 years, broadening the population in which nipocalimab has been studied
* * *
SAVANNAH, Ga. (October 15, 2024) - Johnson & Johnson today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab i . . .